LMLina Matera

Lina Matera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lina Matera has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prolactin in autoimmunity and antitumor defence

    by L Matera, Marcella Mori, M Mori, M Geuna, S Buttiglieri, G Palestro


  • Cooperation of Pituitary Hormone Prolactin with Interleukin‐2 and Interleukin‐12 on Production of Interferon‐γ by Natural Killer and T Cells

    by Lina Matera, Marcella Mori

    Abstract: The pituitary hormone prolactin (PRL) is also produced by cells of the immune system and participates in early and late T cell activating events. We have previously shown a modulatory role of PRL during maturation of dendritic cells (DC). Production of IL‐12 by T cell receptor (TCR)‐activated DC is necessary for T cells to acquire the Th1 cytokine (i.e., IFN‐γ secreting) profile, which is associated with activation of cellular response. In a separate work, PRL has been shown to increase IFN‐γ synthesis by natural killer (NK) cells. We have extended that study by exploring the ability of PRL to induce IFN‐γ production by T and NK cells in the presence of the specific stimuli IL‐12 and IL‐2. The individual effect of PRL, IL‐12, and IL‐2 was specific for NK cells, and IL‐2 and IL‐12 were much more efficient than PRL. Cooperation of IL‐2 and PRL was observed on NK cells. IL‐2‐induced synthesis of IFN‐γ was increased by physiological concentrations of PRL but was unaffected or inhibited by high concentrations. By contrast, optimal enhancement of IL‐12‐induced IFN‐γ release was observed with T cells but not with NK cells. Unexpectedly, interaction between PRL and IL‐12 occurred only at high concentrations of PRL. These data indicate a complex role of PRL in the cytokine network and point to a revaluation of the proposed immunosuppression by stress‐related hyperprolactinemia.


  • Open Access

    Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells

    by Lina Matera, Massimo Geuna, Cristina Pastore, Stefano Buttiglieri, Gianluca Gaidano, Andrea Savarino, Simona Marengo, Barbara K. Vonderhaar

    Prolactin (PRL) interacts with lymphocyte‐signaling molecules and cytokines. Previous work has shown independent and synergistic effects of PRL on the generation of IL‐2‐driven anti‐tumor lymphokine activated killer (LAK) activity by peripheral blood mononuclear cells (PBMC). The potential importance of PRL as a biological immunomodifier, however, is challenged by its ability to influence normal lymphocyte mitogenesis and hence lymphoid tumor growth. Since non‐Hodgkin's lymphoma (NHL) cell lines were efficiently killed by LAK generated with native (n) or recombinant (r) human PRL combined with low, per se ineffective doses of IL‐2, we have addressed here the question of whether PRL acts as a growth factor for LAK targets. NHL cells were analyzed for: 1. expression of the PRL receptor (PRL‐R); 2. responsiveness to nPRL or rPRL; 3. constitutive expression and release of PRL; 4. existence of a PRL autocrine loop. PRL‐R, defined by multiple antibodies, was detected in 3 of 12 NHL cell lines. However, nPRL or rPRL, in a wide range of concentrations (0.75–50 ng/ml), were not mitogenic for growth‐arrested, PRL‐R positive NHL cell lines. PRL mRNA was detected by RT‐PCR in 10 of the 12 cell lines examined with a higher frequency among AIDS‐related NHL cell lines. PRL protein in the immunoprecipitate of 35S‐methionine‐labeled cell lysates and supernatants paralleled mRNA expression, and Western blotting analysis showed the presence of the pituitary/lymphocyte non‐glycosylated (23.5 kDa) and glycosylated (25 kDa) isoforms. Experiments with blocking antibodies showed the independence from endogenous PRL for NHL cell growth. Int. J. Cancer 85:124–130, 2000.


  • Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line

    by Lina Matera, Miguel Cutufia, Massimo Geuna, Maria Contarini, Stefano Buttiglieri, Shawn Galin, Annamaria Fazzari, Cristina Cavaliere


  • Action of Pituitary and Lymphocyte Prolactin

    by Lina Matera

    In vivo and in vitro data combined show that prolactin (PRL) can mimic or interact with known lymphocyte cytokines and that these, in turn, can regulate PRL synthesis at the site of immune response. In contrast, pituitary PRL is under the control of both immune system products (non-cognitive stimuli) and signals to the CNS (cognitive stimuli). The role of PRL as a cytokine and as an endocrine hormone is discussed. In particular, assignment of PRL to the T helper 1 phenotype is proposed, based on its ability to enhance NK cell function, activate the interferon-regulated factor (IRF-1) transcription factor and to interact with or generate IL-2 and IFNy. Since hyperprolactinemia and hypoprolactinemia are both immunosuppressive, physiological levels of circulating PRL must be necessary to maintain normal immunocompetence. Moderate increases in PRL during immune stimulation of the hypothalamic-pituitary axis may counteract glucocorticoid inhibition, whereas inappropriate prolongation of PRL synthesis could lead to autoimmune diseases. Increased release of PRL by the pituitary during stress may inhibit NK cell antitumor cytotoxicity. The variety of PRL isotypes, the existence of multiple receptor subunits, and the complexity of their intracellular signaling may explain the specificity of PRL action on different target cells.